Atect Corp operates in the Biological products exc. diagnostic sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Atect Corp with three other
pharmaceutical manufacturers in Asia:
Ina Research Incorporation
sales of 2.30 billion Japanese Yen [US$20.64 million]
of which 86%
was Non-clinical business),
Pharma Foods International Co.Ltd
(4.72 billion Japanese Yen [US$42.46 million]
of which 73%
was Functional product(Online business)), and
Hester Pharmaceuticals Limited
based in India
(1.23 billion Indian Rupees [US$19.26 million]
of which 88%
was Poultry Vaccines).
Atect Corp reported sales of ¥2.48 billion (US$22.32 million)
March of 2017.
a very small
increase of 0.4%
versus 2016, when the company's sales were ¥2.47 billion.
The sales level in 2017 was fairly close to the level five years ago: in 2012, Atect Corp had sales
of ¥2.50 billion.
Sales of Semiconductor Material saw an increase
that was more than double the company's growth rate: sales were up
3.5% in 2017, from
¥793.50 million to ¥821.57 million.
Not all segments of Atect Corp experienced an increase in sales in 2017:
sales of Health Inspection Equipment fell 1.2% to ¥1.56 billion.
Atect Corp also experienced decreases in sales in
Pim (down 0.6% to ¥105.49 million)